Drug reference

metocurine

Competitive neuromuscular blocking agent (Benzylisoquinoline type) · Neuromuscular blocker

Competitive neuromuscular blocking agent (Benzylisoquinoline type)Neuromuscular blocker

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

10 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 10 →

AmikacinSevereDatabaseDDInter
Botulinum Toxin Type ASevereDatabaseDDInter
Botulinum Toxin Type BSevereDatabaseDDInter
ColistimethateSevereDatabaseDDInter

Mechanism

Binds to the nicotinic acetylcholine receptor in skeletal muscle (Nm) and competitively blocks the binding of acetylcholine. It is three times more potent than tubocurarine.

Indications

Adjuvant in surgical anesthesia to obtain relaxation of skeletal muscle

Dosing

Adult: 0.4 mg/kg (initiation); 0.5–1 mg/kg (intermittent injection)

Pharmacokinetics

Duration

110 min

Excretion

Renal elimination

Side effects

Serious

Less histamine release

Drug interactions

Amikacin

Severe

Database

Clinical effect not specified

Source: DDInter

Botulinum Toxin Type A

Severe

Database

Clinical effect not specified

Source: DDInter

Botulinum Toxin Type B

Severe

Database

Clinical effect not specified

Source: DDInter

Colistimethate

Severe

Database

Clinical effect not specified

Source: DDInter

Kanamycin

Severe

Database

Clinical effect not specified

Source: DDInter

Paromomycin

Severe

Database

Clinical effect not specified

Source: DDInter

Plazomicin

Severe

Database

Clinical effect not specified

Source: DDInter

Polymyxin B

Severe

Database

Clinical effect not specified

Source: DDInter

Streptomycin

Severe

Database

Clinical effect not specified

Source: DDInter

Tobramycin

Severe

Database

Clinical effect not specified

Source: DDInter

2 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.

Related guidelines

Beta-blockers in hypertension

MOHFW · Cardiology · 2024

Benign prostatic hyperplasia

AUA · Urology · 2018

Postpartum haemorrhage

FOGSI · Obstetrics & Gynaecology · 2024

Benign prostatic hyperplasia

EAU · Urology · 2024

Diabetic retinopathy

AIOS · Ophthalmology · 2023

Other Competitive neuromuscular blocking agent (Benzylisoquinoline type) drugs

tubocurarine

0 brands

Ask House about metocurine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team